dociparstat sodium (CX-01) / Cantex Pharma, Jazz - LARVOL DELTA

Targeting the heparan sulfate proteoglycan/heparanase axis as a novel therapeutic strategy to drive adipogenesis and block tumor growth of dedifferentiated liposarcoma. (PubMed, Int J Biol Sci) - "We employed an investigational HS mimetic, the non-anticoagulant heparin CX-01 (dociparstat), to assess its HS competition impact on deregulated adipogenic differentiation and growth of human DDLPS cell lines and patient-derived xenografts (PDXs)...This suggests a role for these genes in disease progression. Collectively, this study demonstrates the remarkable potential of HS competition to simultaneously block multiple anti-adipogenic players representing metabolic vulnerabilities, and to promote a differentiated tumor phenotype markedly less aggressive."

Journal • Liposarcoma • Oncology • Sarcoma • Solid Tumor • COL5A1 • MMP14 • SDC1 • TIMP1

CX-01 mitigates trauma-induced acute kidney injury and improves survival in a combat-relevant polytrauma rat model. (PubMed, Front Pharmacol) - "These results demonstrate that CX-01 treatment might reduce trauma-induced AKI and improve survival in a clinically relevant rat model. Future studies should focus on validation of this approach in large animal models or advancing CX-01 toward clinical trials in trauma patients."

Journal • Preclinical • Acute Kidney Injury • Acute Respiratory Distress Syndrome • Hematological Disorders • Immunology • Inflammation • Musculoskeletal Diseases • Nephrology • Orthopedics • Pulmonary Disease • Renal Disease • Respiratory Diseases • Systemic Inflammatory Response Syndrome • HMGB1

CX-01 Improves Survival and Attenuates Organ Failure in a Rat Polytrauma Model (IMMUNOLOGY 2026) - "CX-01, as an immunotherapeutic, mitigates trauma-induced immune and organ dysfunctions, and may save lives for combat casualties."

Preclinical • Acute Kidney Injury • Acute Respiratory Distress Syndrome • Hematological Disorders • Inflammation • Nephrology • Renal Disease • Respiratory Diseases • HMGB1 • IL10

A novel agricultural commodity price prediction model integrating deep learning and enhanced swarm intelligence algorithm. (PubMed, PLoS One) - "Using historical data from corn and wheat markets as case studies, the experimental findings demonstrate that the proposed SVMD-MSDBO-CNN-BiLSTM-A model significantly outperforms nine baseline approaches. Specifically, it reduces the Mean Absolute Percentage Error (MAPE) by 25.78% and 37.57%, respectively, and enhances directional accuracy (Dstat) by 1.15% and 14.53% compared to the top single models."

Journal

Protective Effect of Low 2-O, 3-O Desulfated Heparin (ODSH) Against LPS-Induced Acute Lung Injury in Mice. (PubMed, Biomolecules) - "ODSH mitigates LPS-induced ALI by reducing vascular permeability, neutrophilic inflammation, and pro-inflammatory signaling while enhancing IL-10 expression. These findings suggest ODSH may offer a novel therapeutic approach for treating ALI."

Journal • Preclinical • Acute Lung Injury • Acute Respiratory Distress Syndrome • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL10 • IL6 • MPO

Antiangiogenic Activity of 6-O-Desulfated Modified Heparin: Suppression of Choroidal Neovascularization. (PubMed, Int J Mol Sci) - "We explored the therapeutic potential of 6-O-desulfated heparin (Hep-6Od) as an antiangiogenic agent with diminished anticoagulant activity...These findings support Hep-6Od as a promising alternative to anti-vascular endothelial growth factor (VEGF) therapies for AMD treatment, potentially expanding current retinal vascular disease interventions. The results underscore its potential to transform AMD management, pending further clinical validation and awaiting confirmation in further studies."

Journal • Age-related Macular Degeneration • Cardiovascular • Macular Degeneration • Ophthalmology • Retinal Disorders • FGF2

Expanding the Role of Heparin Derivatives in Oncology: From Anticoagulation to Antitumor Activity. (PubMed, Pharmaceuticals (Basel)) - "Analysis of the glycosaminoglycan analog dociparstat sodium reveals significant activity in myeloid malignancies, mediated by specific interference with CXCL12/CXCR4 signaling cascades. Significant challenges remain in manufacturing scale-up, analytical validation, and long-term safety assessment. Future studies must address dose optimization, combination strategies, and controlled clinical trials to determine the full therapeutic potential of these compounds in clinical oncology."

Clinical • Journal • Review • Cardiovascular • Hematological Disorders • Hematological Malignancies • Oncology • Thrombosis • CXCL12

Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack. (PubMed, Cell Physiol Biochem) - "While CX-01 prevents GI-ARS lethality, structural modification to extend half-life may be necessary to optimize first responder prophylaxis."

Journal • Gastrointestinal Disorder

Selection with two alleles of X-linkage and its application to the fitness component analysis of OdsH in Drosophila. (PubMed, G3 (Bethesda)) - "Using maximum likelihood estimation (MLE), we determined the fitness components associated with the OdsH alleles in males and females. Our analysis revealed functional aspects of the fitness determinants associated with OdsH, and that sex-specific fertility and viability consequences both contribute to selection on an X-linked gene."

Journal

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov) - P3 | N=9 | Terminated | Sponsor: Chimerix | Active, not recruiting ➔ Terminated; Study enrollment was terminated on 16 May 2022 due to slow recruitment.

Combination therapy • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Distillation on NACI study and outcome of the SENTIX prospective single-arm international trial (CEEGOG CX-01; ENGOT-CX2) (SGO 2024) - No abstract available

Clinical • Oncology

Survival of patients with early-stage cervical cancer after sentinel lymph node biopsy without systematic pelvic lymphadenectomy: Primary endpoint outcome of the SENTIX prospective, single-arm, international trial (CEEGOG CX-01; ENGOT-CX2) (SGO 2024) - "The study fulfilled the primary endpoint which was recurrence rate (RR) at 24th months of follow-up and confirmed the null hypothesis that the RR, being 6.06%, after SLN biopsy is non-inferior to the reference recurrence rate of 7% in patients after PLND. In early-stage cervical cancer patients, SLN biopsy with pathological ultrastaging is safe and accurate method to detect lymph node metastases."

Biopsy • Clinical • Late-breaking abstract • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Tumour Size Assessment In Patients With Early-Stage Cervical Cancer And Its Impact On A Tailored Management: Final Results Of A Prospective, International Multicenter Study SENTIX (CEEGOG CX-01; ENGOT-CX2) (ESGO 2024) - P | "Conclusion The study highlights, that even with the use of modern imaging in preoperative staging, inaccuracy in tumour measurement is a frequent reason for incorrect stage assessment, and consequently for scheduling of inadequate surgery. International guidelines should specify acceptable deviations in tumour size assessment and the threshold for adjuvant treatment for patients who received insufficient radicality of surgery."

Clinical • Cervical Cancer • Oncology • Solid Tumor

Survival Of Patients With Early Stages Cervical Cancer After SLN Biopsy Without Systematic Pelvic Lymphadenectomy: Survival Outcomes Of The SENTIX Prospective Single-Arm International Trial (CEEGOG CX-01; ENGOT-CX2) (ESGO 2024) - P | "Conclusion The study showed that 2-year DFS and OS in patients after SLN biopsy is excellent and comparable to patients after PLND, reported in the recent prospective trials. In early-stage cervical cancer patients, SLN biopsy with pathological ultrastaging and no further lymphadenectomy is not associated with increased risk of recurrence."

Biopsy • Clinical • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A comprehensive evolutionary scenario for the origin and neofunctionalization of the Drosophila speciation gene Odysseus (OdsH). (PubMed, G3 (Bethesda)) - "In conclusion, we have proposed that the origin of OdsH occurred earlier than previously proposed, followed by neofunctionalization. Our results also suggested that its role as a speciation gene might be restricted to D. mauritiana and D. simulans."

Journal

Lower-Limb Lymphedema After Sentinel Lymph Node Biopsy In Cervical Cancer Patients: Final Results Of The SENTIX Prospective International Study (CEEGOG CX-01/ ENGOT-Cx2) (ESGO 2023) - "Conclusion ConclusionSevere persistent LLL occurred rarely after surgical pelvic LN staging in cervical cancer patients. Contrary to our expectations, de-escalation from systematic PLND to SLN biopsy was not associated with a significantly decreased risk of mild-to-moderate LLL."

Biopsy • Clinical • Cervical Cancer • Oncology • Solid Tumor

Magnetic Resonance Imaging Or Expert Ultrasound In Preoperative Local Staging Of Patients With Early-Stage Cervical Cancer: Final Results Of The SENTIX Prospective, Single-Arm, International Trial (CEEGOG CX-01; ENGOT-CX2) (ESGO 2023) - P=N/A | "Combining both imaging methods did not increase the outcome (Table). Conclusion Pelvic MRI and EUS are equally sensitive methods for assessing clinically relevant parameters in preoperative clinical staging of cervical cancer, including tumour size, parametrial involvement, and macrometastatic nodal involvement."

Clinical • MRI • Cervical Cancer • Oncology • Solid Tumor

Platform-agnostic electrochemical sensing app and companion potentiostat. (PubMed, Analyst) - "The versatility of PocketEC, developed with an assay developer mindset, was demonstrated by interfacing it, via Bluetooth, to the ADuCM355 evaluation board, the open-source DStat potentiostat and the Voyager board, a custom-built, small footprint potentiostat based around the LMP91000 chip...Importantly, the versatility of the app makes it a candidate of choice for the development of future portable potentiostats. Finally, the app is available to download on the Google Play store and the source codes and design files for the PocketEC app and the Voyager board are shared via Creative Commons license (CC BY-NC 3.0) to promote the development of novel portable or wearable applications based on electrochemical sensing."

Journal

CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS. (ASCO 2018) - P1; "CX-01 and AZA appears to have an encouraging response rate in HMA-refractory AML/MDS. Treatment was feasible with no instances of study related severe AEs. This trial is ongoing to evaluate the ORR and OS of all patients treated."

Clinical • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

6-O-desulfated heparin attenuates myocardial ischemia/reperfusion injury in mice through the regulation of miR-199a-5p/klotho axis. (PubMed, Glycoconj J) - "In conclusion, these results suggested that 6-O-desulfated heparin with lower anticoagulant activity attenuated myocardial I/R injury through miR-199a-5p/klotho and ROS signaling. Our study may also indicate that 6-O-desulfated heparin, as an excellent heparin derivative, is a potential therapeutic agent for myocardial I/R injury."

Journal • Preclinical • Cardiovascular • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury • MIR199A

WHITE-COAT HYPERTENSION WITHOUT ORGAN DAMAGE: IMPACT OF LONG-TERM MORTALITY, NEW HYPERTENSION AND NEW ORGAN DAMAGE. (PubMed, J Hypertens) - "The present study provides the first evidence that WCH with no cardiac and renal OD is accompanied by an increased long-term risk of mortality, new hypertension and new OD, thereby not representing a clinically innocent condition."

Journal • Cardiovascular • Hypertension

Forecasting Bitcoin Price Using Interval Graph and ANN Model: A Novel Approach. (PubMed, SN Comput Sci) - "We have used three evaluation metrics, such as MAPE, RMSE, and Dstat. The empirical study has clearly demonstrated the encouraging performance and effectiveness of the IG-ANN. The performance is compared with traditional ANN techniques on bitcoin time-series data spanning 2013-2019 and found that IG-ANN is outperforming all."

Journal

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML) (clinicaltrials.gov) - P3 | N=9 | Active, not recruiting | Sponsor: Chimerix | Recruiting ➔ Active, not recruiting | N=570 ➔ 9 | Trial completion date: Feb 2026 ➔ Dec 2022 | Trial primary completion date: May 2024 ➔ Dec 2022

Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - P2 | N=60 | Terminated | Sponsor: Chimerix | Completed ➔ Terminated

Trial termination • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Genetic and Pathogenic Characterisation of a Virulent Akabane Virus Isolated from Goats in Yunnan, China. (PubMed, J Vet Res) - "Phylogenetic analysis based on the ORF sequences of the small segments indicated that the AKAV isolate used was most closely related to the GD18134/2018 Chinese midge and bovine NM BS/1strains, while phylogenetic analysis based on the medium segments showed a close relationship between CX-01 and the Chinese GLXCH01 strain. The CX-01 isolate was related to AKAV genogroup Ia and probably originated from a recombination of different strains."

Journal • CNS Disorders